Article Text

other Versions

PDF
Case report
Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab
  1. Saqib Mumtaz1,
  2. Jason Goh1,
  3. Gideon M Hirschfield2,3,
  4. James Ferguson3,
  5. Sheldon C Cooper1
  1. 1Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  2. 2NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK
  3. 3Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  1. Correspondence to Dr Saqib Mumtaz, Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B152GW, UK; drsaqibmumtaz{at}gmail.com

Abstract

Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC. We present an exemplar case of successful use of vedolizumab in the management of corticosteroid refractory PSC-IBD after liver transplantation.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.